JanOne Inc. (JAN): Price and Financial Metrics


JanOne Inc. (JAN)

Today's Latest Price: $5.23 USD

0.29 (-5.25%)

Updated Jan 25 6:55pm

Add JAN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 18 in Waste Disposal

See all "A" rated Strong Buy stocks

JAN Stock Summary

  • JAN has a higher market value than only 2.66% of US stocks; more precisely, its current market capitalization is $10,101,501.
  • JanOne Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 95.12% of US listed stocks.
  • JAN's price/sales ratio is 0.28; that's higher than the P/S ratio of just 5.7% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to JanOne Inc are SYPR, MYRG, VRTU, ORN, and NSIT.
  • JAN's SEC filings can be seen here. And to visit JanOne Inc's official web site, go to www.janone.com.

JAN Stock Price Chart Interactive Chart >

Price chart for JAN

JAN Price/Volume Stats

Current price $5.23 52-week high $9.10
Prev. close $5.52 52-week low $2.01
Day low $5.22 Volume 110,900
Day high $5.59 Avg. volume 143,333
50-day MA $4.57 Dividend yield N/A
200-day MA $4.08 Market Cap 9.57M

JanOne Inc. (JAN) Company Bio


JanOne Inc. develops treatments for conditions that cause severe pain. The company, through its non-addictive pain-relieving drugs, focuses on reduction for need of opioid prescriptions to treat disease associated pain that can lead to opioid abuse. Its lead candidate JAN101 provides slow-release formulation of sodium nitrite therapeutic for treatment of peripheral artery disease (PAD). The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.


JAN Latest News Stream


Event/Time News Detail
Loading, please wait...

JAN Latest Social Stream


Loading social stream, please wait...

View Full JAN Social Stream

Latest JAN News From Around the Web

Below are the latest news stories about JanOne Inc that investors may wish to consider to help them evaluate JAN as an investment opportunity.

JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started production of JAN101 under Current Good Manufacturing Practices (cGMP) for the company's anticipated Phase 2b trials to treat Peripheral Artery Disease (PAD) and as a potential treatment for Covid-19 vascular complications.

Yahoo | September 24, 2020

JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease

LAS VEGAS, Sept. 22, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has issued its September 2020 Shareholder Letter….

PR Newswire | September 22, 2020

JanOne Announces Strategic Plan to Divest its Legacy Businesses

LAS VEGAS, Sept. 16, 2020 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, provided an update today regarding its initiatives to pursue a strategic…

PR Newswire | September 16, 2020

JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials

LAS VEGAS , Sept. 3, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ: JAN ), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability of its developmental batch run of JAN101. Working closely with selected bottling and labeling partner, Eurofins CDMO, the company is currently on track to initiate GMP production of JAN101 to support planned Phase 2b trials to treat peripheral artery disease (PAD). Required clinical batches of properly bottled and labeled product will also be available to support immediate start of clinical research to use JAN101 as a potential treatment for Covid-19 vascular complications should JanOne gain FDA IND approval. The company is currently finalizing its Covid-19 v...

Benzinga | September 3, 2020

JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101

JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, announces a internal name change for its current drug candidate from TV1001SR to JAN101, soon to enter Phase 2b clinical trials as a potential treatment Peripheral Artery Disease (PAD). The name change will be effective immediately and will be used in all its current and future clinical trials, Indications for a New Drug, clinical and research studies planned to be conducted in the future.

Yahoo | August 4, 2020

Read More 'JAN' Stories Here

JAN Price Returns

1-mo N/A
3-mo 43.29%
6-mo 35.49%
1-year 66.03%
3-year 0.58%
5-year 26.02%
YTD 6.95%
2020 65.20%
2019 34.55%
2018 -57.69%
2017 -7.14%
2016 6.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8679 seconds.